Screener
Denali Therapeutics Inc. DNLI Business Segments — Research and Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | Therapeutics Segment / Three Months Ended June 30, 2026 | Therapeutics Segment / Three Months Ended June 30, 2025 | Therapeutics Segment / Six Months Ended June 30, 2026 | Therapeutics Segment / Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| External research and development expenses - TV programs, including cost sharing | 40,419 | 37,594 | 78,883 | 84,052 |
| Other research and development expenses, including small molecule programs | 16,494 | 24,847 | 40,048 | 54,347 |
| Personnel related research and development expenses | 40,106 | 40,255 | 81,934 | 80,524 |
| Total research and development expenses | 97,019 | 102,696 | 200,865 | 218,923 |
| Personnel related selling, general and administrative expenses | 22,921 | 20,115 | 45,485 | 38,853 |
| Other selling, general and administrative expenses | 13,362 | 12,152 | 24,309 | 22,767 |
| Total selling, general and administrative expenses | 36,283 | 32,267 | 69,794 | 61,620 |
| Intangible asset amortization | $750 | — | $750 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s business segments — research and development expense?
- Denali Therapeutics Inc. (DNLI) reported business segments — research and development expense of $97.02M in Q2 2026.
- How has Denali Therapeutics Inc.'s business segments — research and development expense changed year-over-year?
- Denali Therapeutics Inc.'s business segments — research and development expense decreased by 5.5% year-over-year, from $102.7M to $97.02M.
- What is the long-term trend for Denali Therapeutics Inc.'s business segments — research and development expense?
- Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s business segments — research and development expense has grown at a 5.3% compound annual growth rate (CAGR), from $358.73M to $418.78M.
- What does business segments — research and development expense mean?
- The total aggregate cost of all research and development activities, including internal personnel, external collaborations, and overhead. This is a primary indicator of the company's commitment to advancing its clinical and preclinical pipeline. Investors use this to evaluate the company's burn rate and the scale of its scientific investment.
Ask your AI about Denali Therapeutics Inc.'s business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude